"I’d like to thank the staff for talking me through my surgery. They took my fear away by letting me know up front just what to expect. It was such a big help and relief! Dr. Hsu and the entire staff are amazing and dedicated to what they do. The patients at Mid Atlantic Retina... read more
Dr. Carl Regillo, a study investigator for Genentech’s first refillable eye implant, discusses the promising results in a phase 2 trial. The Port Delivery System is designed to deliver a new formulation of Lucentis' active ingredient, ranibizumab, continuously to wet age-related macular degeneration patients to avoid monthly eye injections. Read more about the new surgical implant here.